D.E. Shaw & Co
MCRB icon

D.E. Shaw & Co’s Seres Therapeutics MCRB Stock Holding History

D.E. Shaw & Co’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-24,318
Closed -$376K – 4689
2024
Q1 		$376K Buy
24,318
+15,892
+189% +$343K ﹤0.01% 3621
2023
Q4 		$236K Buy
+8,426
New +$221K ﹤0.01% 3827
2022
Q3 		– Sell
-2,157
Closed -$148K – 5380
2022
Q2 		$148K Sell
2,157
-2,625
-55% -$226K ﹤0.01% 4646
2022
Q1 		$681K Buy
4,782
+3,325
+228% +$511K ﹤0.01% 4179
2021
Q4 		$243K Buy
1,457
+648
+80% +$103K ﹤0.01% 4783
2021
Q3 		$113K Sell
809
-1,815
-69% -$355K ﹤0.01% 4701
2021
Q2 		$1.25M Buy
2,624
+18
+0.7% +$7.59K ﹤0.01% 3357
2021
Q1 		$1.07M Sell
2,606
-17,144
-87% -$7.89M ﹤0.01% 3057
2020
Q4 		$9.68M Sell
19,750
-5,147
-21% -$3.01M 0.01% 1398
2020
Q3 		$14.1M Sell
24,897
-15,861
-39% -$5.27M 0.01% 1018
2020
Q2 		$3.88M Buy
40,758
+16,299
+67% +$1.43M ﹤0.01% 1855
2020
Q1 		$1.75M Buy
24,459
+6,388
+35% +$428K ﹤0.01% 2275
2019
Q4 		$1.25M Buy
18,071
+5,172
+40% +$384K ﹤0.01% 2827
2019
Q3 		$1.03M Sell
12,899
-2,892
-18% -$191K ﹤0.01% 2806
2019
Q2 		$1.02M Buy
15,791
+1,526
+11% +$145K ﹤0.01% 2668
2019
Q1 		$1.96M Sell
14,265
-1,132
-7% -$138K ﹤0.01% 2172
2018
Q4 		$1.39M Buy
15,397
+860
+6% +$120K ﹤0.01% 2430
2018
Q3 		$2.21M Buy
14,537
+89
+0.6% +$14.4K ﹤0.01% 2132
2018
Q2 		$2.48M Sell
14,448
-567
-4% -$92.6K ﹤0.01% 2059
2018
Q1 		$2.2M Sell
15,015
-4,007
-21% -$768K ﹤0.01% 1983
2017
Q4 		$3.86M Sell
19,022
-8,415
-31% -$1.73M 0.01% 1670
2017
Q3 		$8.8M Buy
27,437
+1,074
+4% +$294K 0.01% 1022
2017
Q2 		$5.96M Sell
26,363
-2,552
-9% -$524K 0.01% 1218
2017
Q1 		$6.52M Buy
28,915
+1,996
+7% +$405K 0.01% 1117
2016
Q4 		$5.33M Buy
26,919
+654
+2% +$143K 0.01% 1319
2016
Q3 		$6.46M Buy
26,265
+25,790
+5,429% +$9.05M 0.01% 1135
2016
Q2 		$276K Buy
+475
New +$279K ﹤0.01% 3065

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

D.E. Shaw & Co's MCRB Position: Q2 2024 in Review

D.E. Shaw & Co sold out of Seres Therapeutics (MCRB) in Q2 2024, closing a stake of 24,318 shares — an estimated $376K sold.

D.E. Shaw & Co first reported a position in MCRB in Q2 2016 and held it in 27 quarters. The position peaked at $14.1M in Q3 2020. 93 funds tracked by Wall St. Rank hold MCRB as of Q2 2024.

  • D.E. Shaw & Co reported no remaining Seres Therapeutics position as of Q2 2024 after selling out during the quarter.
  • D.E. Shaw & Co sold 24,318 Seres Therapeutics shares in Q2 2024, an estimated $376K.
  • D.E. Shaw & Co first reported a position in Seres Therapeutics in Q2 2016 and held it in 27 quarters.
  • D.E. Shaw & Co's Seres Therapeutics position peaked at $14.1M in Q3 2020.
  • 93 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2024.

Based on D.E. Shaw & Co's 13F filing for Q2 2024, filed 14 Aug 2024.